Ubiquitome to Participate at BIO International Convention 2019

AUCKLAND, New Zealand, May 31, 2019 /PRNewswire/ — New Zealand-based developer Ubiquitome will be exhibiting at the 2019 BIO International Convention in Philadelphia from 3 – 6 June. This event attracts 16,000+ attendees from over 7,000 businesses worldwide, including the leading biotech and pharma companies.

The Convention celebrates globally important innovations in biotech that start with ‘one’: one meeting, one theory, one trial, one breakthrough.

Ubiquitome will be showcasing its breakthrough ‘Personal’ Genomics Device, the Liberty16. Building on the mobile design philosophy of the company’s ground-breaking Freedom4, the Liberty16 brings unprecedented affordability and flexibility to genomic testing.

The Liberty16 comes with built-in lithium ion batteries for two to three hours of mobile running time, as well as Bluetooth paired with an iPhone app, meaning samples can be run and tested in the field.

An open platform with gold standard performance, the Liberty16 is compatible with industry standard consumables and chemistries such as Taqman® and SYBR.

Where: Pennsylvania Convention Center, Philadelphia, PA
When: 3 – 6 June, 2019
Ubiquitome: Booth #4014

For more information on the BIO International Convention, please visit: http://convention.bio.org/.

ABOUT UBIQUITOME
Ubiquitome is a New Zealand-based developer of handheld, cloud-connected, real-time PCR devices. Ubiquitome’s mission is to enable universal access to genomic information through ubiquitous cloud connected, genetic analysis devices. Visit www.ubiquitomebio.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ubiquitome-to-participate-at-bio-international-convention-2019-300859680.html

SOURCE Ubiquitome

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

11 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

14 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

14 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

14 hours ago